Additionally, the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trial showed that, in people with type 2 diabetes and worsening HF, sotagliflozin reduced the total number of cardiovascular deaths or hospitalisations or urgent visits for HF compared with placebo regardless of ejection fraction [150]
PMID 17584130
Fatigue Primary issue: energy depletion Typical documentation: tired, low stamina, sleepiness, exhausted. Better code family: fatigue/malaise codes (not M62.81) Muscle weakness Primary issue: strength reduction Typical documentation: objective deficits on strength testing, functional impairment Better code: M62.81 when weakness is generalized Deconditioning Primary issue: performance decline after inactivity, illness, or hospitalization Documentation must still show objective weakness/functional decline if M62.81 is used
Muscle mass is often lost during weight loss
Los AR de GLP-1 existen porque los GLP-1 endgenos tienen una vida media corta, los descomponen rpidamente las enzimas DPP4 (otra clase de medicamentos para la diabetes Tipo 2) y las personas con diabetes de tipo 2 tienen cantidades ms bajas de GLP-1 natural que las personas sin diabetes
Are semaglutide and tirzepatide FDA-approved for weight loss
